SLRX: Salarius P/S Multiple
The absence of commercial products leaves Salarius Pharmaceuticals (SLRX) dependent on venture capital investments. The current P/S valuation on the GURU.Markets terminal illustrates a chart of the metric, where the value 20.40 represents the most recent figure. Business stability is supported by the non-cyclical nature of oncology, while trial safety is guaranteed by strict adherence to the cold chain during component transportation.
Analytical breakdowns for Salarius (SLRX)
- price and consensus price forecast:
- market capitalization information:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Salarius Pharmaceuticals|SLRX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Salarius Pharma|SLRX - Company Total Debt|Debts to Book Capitalization Salarius|SLRX - Company Long-Term Debt|Short-Term Debt Volume Salarius Pharmaceuticals|Intermediate Coverage Ratio salariuspharma.com
- financial results and valuation multiples details:
SLRX - Company Net Income|Forward Earnings Salarius Pharmaceuticals|SLRX - P/E Multiple|Future Price to Earnings Multiple Salarius Pharmaceuticals Inc|SLRX - PEG Multiple|EV/EBITDA Multiple Salarius|SLRX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Salarius Pharmaceuticals|SLRX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months salariuspharma.com|SLRX - Earnings growth in current year|Earnings growth forecast for next year Salarius Pharmaceuticals
- issuer revenue and sales details:
Summary company analytics:SLRX salariuspharma.com
The P/S ratio correlates the market capitalization of Salarius Pharmaceuticals (SLRX) with its revenue, revealing valuation premiums relative to operational efficiency. Analyzing the company's historical P/S value helps identify capital correction risks in the absence of sales growth, which is critical for assessing the expansion potential of Ewing sarcoma drugs and solid tumor therapies within oncology centers.
Competitors of Salarius Pharmaceuticals
Price-to-Revenue Coefficient beigene.com|P/S Multiple HALO (Halozyme)|P/S Multiple Revolution Medicines Inc RVMD|AAPG - Price-to-Revenue Ratio|CGON: Price-to-Revenue Ratio|URGN: P/S Multiple|bicara.com (BCAX) - P/S Multiple|Price-to-Revenue Ratio Personalis|ERAS: Market Capitalization-to-Revenue Ratio|P/S Multiple DCTH|Price-to-Revenue Coefficient Y-mAbs Corp|Aura Biosciences, Inc. - Market Cap to Revenue|P/S Multiple Candel Therapeutics Inc. CADL|ARAY - Price-to-Revenue Ratio|Price-to-Revenue Coefficient SELLAS Life Sciences SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Citius Oncology Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio TuHURA Biosciences Inc.|protaratx.com - Price-to-Sales Ratio|P/S Multiple FATE|WHWK (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple TCRX (TScan Therapeutics, Inc.)|P/S Multiple Champions Oncology Inc CSBR|XBIT - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio CVM (CEL-SCI Corporation)|OS Therapies (OSTX) - Price-to-Revenue Ratio|Market Cap to Revenue radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - P/S Multiple|P/S Multiple Adlai Nortye Limited|P/S Multiple VERU|Market Cap to Revenue tempesttx.com TPST|P/S Multiple XLO (Xilio Therapeutics)|Renovaro Biosciences (RENB) - Price to Sales|MURA: Market Cap to Revenue|KAPA - P/S Multiple|OKUR (onkuretherapeutics.com) - Market Cap to Revenue|GDTC: Market Cap to Sales Volume|CRIS (Curis Inc.) - P/S Multiple|Apollomics Corp (APLM) - Price-to-Revenue Coefficient|P/S Multiple THAR|Market Cap to Revenue advanbiomed.com ADVB|P/S Multiple GNPX (Genprex, Inc.)|P/S Multiple Calidi Biotherapeutics Inc. CLDI|SBFM - Price-to-Revenue Ratio|XBIO: Price-to-Revenue Ratio|Purple Biotech Corp (PPBT) - Price-to-Revenue Ratio|AONC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio BeiGene, Ltd.|checkpointtx.com (CKPT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Elevation Oncology (ELEV)|Price-to-Revenue Ratio ICAD (icadmed.com)|Price-to-Revenue Ratio Ikena Oncology IKNA|Market Capitalization-to-Revenue Ratio NTBL|VIRX: Market Cap to Revenue|MOR (morphosys.com) - Market Cap to Revenue Ratio|NAYA: P/S Multiple|Market Cap to Revenue Ascentage Pharma Group International
